Physician profile

Morgan Arnold

Dermatology · Wenatchee, WA

NPI 1811398431

$840.95

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$50.51

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $492.11 2019-2020
Novartis Pharmaceuticals Corporation $79.25 2019
Celgene Corporation $61.54 2019
Regeneron Healthcare Solutions, INC. $56.83 2019
Organogenesis INC. $33.25 2023 Puraply
Ortho Dermatologics, A Division of Bausch Health US, LLC $30.00 2019
Genzyme Corporation $27.28 2019
Ucb, INC. $19.86 2020
Incyte Corporation $17.26 2024 Opzelura
Sun Pharmaceutical Industries INC. $12.66 2019
Pfizer INC. $10.91 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Morgan Arnold

$840.95

in general payments reported 2019-2025

Years
2019-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/3360248/morgan-arnold

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.